logo
Plus   Neg
Share
Email

FDA Okays Amgen And Allergan's Kanjinti, Biosimilar To Herceptin

Amgen (AMGN) and Allergan plc (AGN) said that the U.S. Food and Drug Administration approved Kanjinti or trastuzumab-anns for all approved indications of the reference product, Herceptin or trastuzumab for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Amgen has a total of 10 biosimilars in its portfolio, three of which have been approved in the U.S. and three that are approved in the European Union.

The company said that Kanjinti is currently not available commercially.

In the U.S., KANJINTI is approved for Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brick-and-mortar retailers reported mixed results as they head into the holiday season, as department store chain Kohl's Corp. (KSS) and Home Depot Inc.'s (HD) sales dropped, while discount retailer TJX Cos. (TJX) recorded strong sales growth. Shares of Home Depot slipped 5% after the home-improvement... The U.S. government has issued a new 90-day license extension that will allow U.S. companies to continue doing business with Chinese telecom giant Huawei Technologies Co. Ltd. This is the third 90-day license extension given by the U.S. to Huawei, the world's largest telecom equipment maker. The extension was given in order to minimize disruption for Huawei's customers. Chick-fil-A said it will no longer donate money to two Christian organizations that have been accused of anti-LGBTQ stances - the Fellowship of Christian Athletes and the Salvation Army. The two organizations have been criticized for their statements about same-sex marriage and homosexuality in the past. Chick-fil-A too faced a backlash after its CEO Dan Cathy said he opposed same-sex marriage.
Follow RTT
>